Myocardial protection by protykin, a novel extract of trans-resveratrol and emodin.
Protykin is an all-natural, high potency standardized extract of trans-resveratrol (20%) and emodin (10%) derived from the dried rhizome of Polygonum cuspidatum. Previous studies have demonstrated free radical scavenging and anti-inflammatory activities of resveratrol. Since free radicals play a crucial role in the pathogenesis of myocardial ischemia/reperfusion injury, we examined whether Protykin could preserve the heart during ischemic arrest. Sprague-Dawley rats were divided into two groups: experimental group was gavaged Protykin (100 mg/kg body wt) dissolved in corn oil for three weeks, while the control group was gavaged corn oil alone. After three weeks, rats were sacrificed, isolated hearts perfused via working mode, were made globally ischemic for 30 min followed by 2 h of reperfusion. Left ventricular functions were continuously monitored and malonaldehyde (MDA) (presumptive marker for oxidative stress) formation were estimated. At the end of each experiment, myocardial infarct size was measured by TTC staining method. Peroxyl radical scavenging activity of Protykin was determined by examining its ability to remove peroxyl radical generated by 2,2'-azobis (2-amidinopropane) dihydrochloride, while hydroxy radical scavenging activity was tested with its ability to reduce 7-OH*-coumarin-3-carboxylic acid. The results of our study demonstrated that the Protykin group provided cardioprotection as evidenced by improved post-ischemic left ventricular functions (dp, dp/dt(max)) and aortic flow as compared to control group. This was further supported by the reduced infarct size in the Protykin group. Formation of MDA was also reduced by Protykin treatment. In vitro studies demonstrated that Protykin possessed potent peroxyl and hydroxyl radical scavenging activities. The results of this study indicate that Protykin can provide cardioprotection, presumably by virtue of its potent free radical scavenging activity.
Sato
M
M
University of Connecticut School of Medicine, Farmington, USA.
Maulik
G
G
Bagchi
D
D
Das
D K
DK
D000818:Animals; D000975:Antioxidants / Q000494:pharmacology / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D003331:Coronary Vessels / Q000503:physiopathology; D004642:Emodin / Q000494:pharmacology* / Q000627:therapeutic use; D005452:Fluoresceins / Q000378:metabolism; D016166:Free Radical Scavengers / Q000378:metabolism; D005720:Gamma Rays; D017665:Hydroxyl Radical / Q000378:metabolism; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D009203:Myocardial Infarction / Q000628:therapy; D017202:Myocardial Ischemia / Q000188:drug therapy*; D018384:Oxidative Stress; D010545:Peroxides / Q000378:metabolism; D019664:Polygonaceae / Q000737:chemistry; D051381:Rats; D017207:Rats, Sprague-Dawley; D015427:Reperfusion Injury / Q000188:drug therapy; D000077185:Resveratrol; D013267:Stilbenes / Q000494:pharmacology* / Q000627:therapeutic use
D000975:Antioxidants; D005452:Fluoresceins; D016166:Free Radical Scavengers; D010545:Peroxides; D013267:Stilbenes; C049375:perhydroxyl radical; D017665:Hydroxyl Radical; D008315:Malondialdehyde; D004642:Emodin; D000077185:Resveratrol